The AP5Z1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population that disrupts the AP5Z1 gene in A-549 lung carcinoma cells. This heterogeneous pool of gene-edited cells eliminates functional AP5Z1 expression, providing a loss-of-function model for studying adaptor protein complex 5 (AP-5) biology. The polyclonal format maintains genetic variation while avoiding single-cell cloning artifacts, enabling robust population-level analyses.
The A-549 parental line originates from human alveolar epithelial carcinoma and is a well-established non-small cell lung cancer (NSCLC) model. It carries a KRAS G12S mutation and wild-type p53, recapitulating a frequent oncogenic driver landscape. A-549 cells retain type II pneumocyte characteristics and are widely utilized for trafficking, autophagy, and drug response studies due to their moderate basal autophagy and endolysosomal pathway integrity.
AP5Z1 encodes the ?? subunit of AP-5, a heterotetramer including AP5B1, AP5M1, and AP5S1. AP-5 localizes to late endosomes and mediates retrograde transport of cargo such as ATG9A and lysosomal membrane proteins (LAMP1, LAMP2) to the trans-Golgi network. It directly interacts with SPG11/spatacsin and SPG15/spastizin, proteins mutated in hereditary spastic paraplegia. mTORC1 signaling serves as an upstream regulator, and loss of AP5Z1 disrupts ATG9A trafficking, impairs autophagic maturation, and leads to accumulation of LC3-II and p62, ultimately causing lysosomal dysfunction. This molecular pathology underlies SPG48.
In the context of KRAS-mutant A-549 cells, AP5Z1 knockout enables dissection of crosstalk between oncogenic signaling and endolysosomal pathways. Since KRAS-driven tumors often depend on autophagy for survival, AP-5 loss may alter autophagic setpoints or reveal compensatory adaptations. The p53 wild-type background avoids confounding p53-regulated autophagy effects, allowing precise assessment of AP-5 contributions in NSCLC.
This model supports diverse research applications, including mechanistic studies of endosomal protein sorting and autophagy regulation. Key assays include immunofluorescence for AP-5 complex localization, Western blotting for LC3-II and p62, lysosomal staining with LysoTracker, co-immunoprecipitation for subunit interactions, RT-qPCR for expression verification, and flow cytometry for autophagy flux. It is also suitable for SPG48 disease modeling and CRISPR-based functional genomics screening. For further information, please contact Ascent Research.
